I need to read through the filing carefully to extract key financial data before writing the article. The filing is a 10-Q for Cartesian Therapeutics, Inc. (NASDAQ:RNAC) for the quarterly period ended September 30, 2026. However, the filing content provided appears to be primarily the cover page, table of contents, and forward-looking statements section - the actual financial statements and MD&A content are referenced but not included in the extracted text. Let me assess the substantive disclosure content. The filing does contain some substantive facts: the company is Cartesian Therapeutics, Inc., filing a 10-Q for Q3 ended September 30, 2026, with 30,503,005 shares outstanding as of October 31, 2026, trading as RNAC on Nasdaq, classified as a non-accelerated filer and smaller reporting company, and references a Loan Agreement with K2 HealthVentures LLC. The forward-looking statements section names specific risk factors that constitute substantive disclosure. This is above the 150-word threshold for substantive content.

Cartesian Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of October 31, 2026, the company had 30,503,005 shares of common stock, par value $0.0001 per share, outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and not an emerging growth company.
  • Loan agreement disclosed: The filing references a Loan Agreement with K2 HealthVentures LLC (K2HV), including compliance covenants that the company identifies as a risk factor.
  • Contingent value rights: The company has contingent value rights (CVRs) registered under Section 12(g) of the Exchange Act, issued to holders of record as of the close of business on December 4, 2023.
  • Development-stage status: The company describes itself as a development-stage company and discloses an expectation to incur losses in the future.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Cartesian Therapeutics Q3 2026: Filing Details and Key Disclosures

Cartesian Therapeutics, Inc., listed on NASDAQ:RNAC with common stock carrying a par value of $0.0001 per share, filed its quarterly report for the period ended September 30, 2026. The filing was submitted to the SEC on November 5, 2026, and covers financial statements for the three and nine months ended September 30, 2026, compared to the same periods in 2025, according to the filing. The company is headquartered at 7495 New Horizon Way, Frederick, MD 21703.

The filing discloses a Loan Agreement with K2 HealthVentures LLC, which the company identifies as carrying compliance covenants that "could adversely affect our operations and, in the case of an event of default, could result in us being obligated to repay any outstanding indebtedness sooner than planned." The company also notes uncertainty regarding access to future capital as a disclosed risk. Additionally, the filing references contingent value rights registered under Section 12(g) of the Act, originally issued to holders of record as of the close of business on December 4, 2023, with any future payouts identified as subject to uncertainty.

The company disclosed that it is a development-stage company and stated an expectation to incur losses going forward, adding that it may never achieve or maintain profitability. Among the other risk factors cited in the quarterly report are the company's dependence on third parties including contract research organizations, its ability to enroll patients in clinical trials, and regulatory requirements from the FDA. The filing contains forward-looking statements that are the company's own and are subject to its cautionary language, including risks described under the "Risk Factors" and "Management's Discussion and Analysis" sections of the report.

What Was Disclosed

Cartesian Therapeutics filed its Form 10-Q for Q3 2026, reporting 30,503,005 shares outstanding as of October 31, 2026, disclosing a Loan Agreement with K2HV, and identifying development-stage losses and clinical-stage risk factors as key areas of uncertainty.